This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
by Zacks Equity Research
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
by Zacks Equity Research
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
by Urmimala Biswas
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
ECL Stock Gains Following Latest Launch to Boost Data Center Cooling
by Zacks Equity Research
Ecolab's 3D TRASAR technology expands its cooling solutions, aiming to optimize data centers and cut resource demand.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.
Waters (WAT) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
by Zacks Equity Research
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
by Zacks Equity Research
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
Ensign Enhances Presence With 3 New Acquisitions in 2 States
by Zacks Equity Research
ENSG adds three skilled nursing facilities in Idaho and California, boosting its U.S. footprint and fueling future growth.
Here's Why You Should Hold Cigna Stock in Your Portfolio for Now
by Zacks Equity Research
CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
by Zacks Equity Research
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
by Zacks Equity Research
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
by Zacks Equity Research
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
by Zacks Equity Research
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
by Zacks Equity Research
MD rises 5.6% YTD as earnings beat, hospital deals and lower costs drive growth. The Zacks Rank #2 signals strong near-term prospects.
Here's Why Encompass Health Shares Are Attracting Investors Now
by Zacks Equity Research
EHC stock jumps 28.8% YTD as investors rally behind strong earnings beat, raised 2025 guidance and a growing national rehab hospital footprint.
BioSig Stock Surges Following Share Exchange Deal With Streamex
by Zacks Equity Research
BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
by Zacks Equity Research
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
by Zacks Equity Research
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
PacBio Stock Slips Despite New China Distribution Deal With Haorui
by Zacks Equity Research
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.